232 related articles for article (PubMed ID: 25681529)
1. Neurocognitive effects of acute choline supplementation in low, medium and high performer healthy volunteers.
Knott V; de la Salle S; Choueiry J; Impey D; Smith D; Smith M; Beaudry E; Saghir S; Ilivitsky V; Labelle A
Pharmacol Biochem Behav; 2015 Apr; 131():119-29. PubMed ID: 25681529
[TBL] [Abstract][Full Text] [Related]
2. CDP-choline: effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression.
Knott V; Smith D; de la Salle S; Impey D; Choueiry J; Beaudry E; Smith M; Saghir S; Ilivitsky V; Labelle A
J Psychopharmacol; 2014 Dec; 28(12):1095-108. PubMed ID: 25315828
[TBL] [Abstract][Full Text] [Related]
3. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
J Psychopharmacol; 2019 Jun; 33(6):688-699. PubMed ID: 30920339
[TBL] [Abstract][Full Text] [Related]
4. An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
J Psychopharmacol; 2023 Apr; 37(4):381-395. PubMed ID: 36927273
[TBL] [Abstract][Full Text] [Related]
5. Combining CDP-choline and galantamine, an optimized α7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
Int J Psychophysiol; 2019 Nov; 145():70-82. PubMed ID: 30790597
[TBL] [Abstract][Full Text] [Related]
6. Effects of acute CDP-choline treatment on resting state brain oscillations in healthy volunteers.
Knott V; Salle S; Smith D; Choueiry J; Impey D; Smith M; Beaudry E; Saghir S; Ilivitsky V; Labelle A
Neurosci Lett; 2015 Mar; 591():121-125. PubMed ID: 25700947
[TBL] [Abstract][Full Text] [Related]
7. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.
Deutsch SI; Schwartz BL; Schooler NR; Brown CH; Rosse RB; Rosse SM
Schizophr Res; 2013 Aug; 148(1-3):138-44. PubMed ID: 23768813
[TBL] [Abstract][Full Text] [Related]
8. CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
Psychopharmacology (Berl); 2020 Dec; 237(12):3665-3687. PubMed ID: 32851421
[TBL] [Abstract][Full Text] [Related]
9. Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.
Deutsch SI; Rosse RB; Schwartz BL; Schooler NR; Gaskins BL; Long KD; Mastropaolo J
Eur Neuropsychopharmacol; 2008 Feb; 18(2):147-51. PubMed ID: 17656074
[TBL] [Abstract][Full Text] [Related]
10. Assessing the acute effects of CDP-choline on sensory gating in schizophrenia: A pilot study.
Aidelbaum R; Labelle A; Baddeley A; Knott V
J Psychopharmacol; 2018 May; 32(5):541-551. PubMed ID: 29338621
[TBL] [Abstract][Full Text] [Related]
11. First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy.
Deutsch SI; Schwartz BL; Schooler NR; Rosse RB; Mastropaolo J; Gaskins B
Clin Neuropharmacol; 2008; 31(1):34-9. PubMed ID: 18303489
[TBL] [Abstract][Full Text] [Related]
12. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
13. CDP-choline: pharmacological and clinical review.
Secades JJ; Frontera G
Methods Find Exp Clin Pharmacol; 1995 Oct; 17 Suppl B():1-54. PubMed ID: 8709678
[TBL] [Abstract][Full Text] [Related]
14. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers.
Dunbar G; Boeijinga PH; Demazières A; Cisterni C; Kuchibhatla R; Wesnes K; Luthringer R
Psychopharmacology (Berl); 2007 May; 191(4):919-29. PubMed ID: 17225162
[TBL] [Abstract][Full Text] [Related]
15. Modafinil and cognitive enhancement in schizophrenia and healthy volunteers: the effects of test battery in a randomised controlled trial.
Lees J; Michalopoulou PG; Lewis SW; Preston S; Bamford C; Collier T; Kalpakidou A; Wykes T; Emsley R; Pandina G; Kapur S; Drake RJ
Psychol Med; 2017 Oct; 47(13):2358-2368. PubMed ID: 28464963
[TBL] [Abstract][Full Text] [Related]
16. CDP-choline attenuates scopolamine induced disruption of prepulse inhibition in rats: involvement of central nicotinic mechanism.
Uslu G; Savci V; Buyukuysal LR; Goktalay G
Neurosci Lett; 2014 May; 569():153-7. PubMed ID: 24708927
[TBL] [Abstract][Full Text] [Related]
17. The acute dose and baseline amplitude-dependent effects of CDP-choline on deviance detection (MMN) in chronic schizophrenia: A pilot study.
Aidelbaum R; Labelle A; Choueiry J; Knott V
Exp Clin Psychopharmacol; 2022 Apr; 30(2):235-248. PubMed ID: 33630646
[TBL] [Abstract][Full Text] [Related]
18. The effects of nicotine on cognition are dependent on baseline performance.
Niemegeers P; Dumont GJ; Quisenaerts C; Morrens M; Boonzaier J; Fransen E; de Bruijn ER; Hulstijn W; Sabbe BG
Eur Neuropsychopharmacol; 2014 Jul; 24(7):1015-23. PubMed ID: 24766971
[TBL] [Abstract][Full Text] [Related]
19. A test of the cognitive-enhancing potential of low-dose mecamylamine in healthy non-smokers.
Yuille MB; Olmstead CK; Wells AK; Hahn B
Psychopharmacology (Berl); 2017 Jan; 234(1):109-116. PubMed ID: 27678550
[TBL] [Abstract][Full Text] [Related]
20. Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.
Preskorn SH; Gawryl M; Dgetluck N; Palfreyman M; Bauer LO; Hilt DC
J Psychiatr Pract; 2014 Jan; 20(1):12-24. PubMed ID: 24419307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]